ClinicalTrials.gg
CompletedNCT05819775Updated Jun 2, 2026Results posted

CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema

A Phase 3 interventional study of CSL312 in Hereditary Angioedema (HAE), sponsored by CSL Behring. Completed at 13 sites in 5 countries. Open to participants aged 2 Years to 11 Years. Per ClinicalTrials.gov, last updated 2026-06-02.

Sponsored by CSL Behring (part of CSL Limited) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
2 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Angioedemas, Hereditary by CSL Limited — 1 open to participants now, 1 under way, none of them phase 3. Angioedemas, Hereditary · CSL Limited.

Started
2023
the only one that year
Phase 3
5 of 11
none open now
Registered
8th of 11
by date

Among the 11 studies in Angioedemas, Hereditary by CSL Limited, this one is the only one that started in 2023, is one of 5 in phase 3, and was the 8th registered.

Angioedemas, Hereditary

171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.

Browse Angioedemas, Hereditary studies →

Open to participants now

1 of the 11 studies in Angioedemas, Hereditary by CSL Limited is open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.

This study: 2 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Angioedemas, Hereditary by CSL Limited, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the safety, PK / PD, and efficacy of SC CSL312 for prophylactic treatment of pediatric subjects with HAE.

03

Conditions studied

  • Hereditary Angioedema (HAE)
04

Who can participate

Ages eligible
2 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female
  2. Aged 2 to 11 years, inclusive, with body weight ≥ 10th percentile based on age
  3. Diagnosed with clinically confirmed C1-INH HAE
  4. Experienced ≥ 2 HAE attacks during the 6 months before Screening

Exclusion criteria

Exclusion Criteria:

  1. Concomitant diagnosis of another form of angioedema, such as idiopathic or acquired angioedema, recurrent angioedema associated with urticaria, or HAE type 3
  2. Use of C1-INH products, androgens, antifibrinolytics, approved or future approved medications, or other small molecule medications for routine prophylaxis against HAE attacks within a minimum of 2 weeks before the Treatment Period
  3. Participation in another interventional clinical study during the 30 days before the Treatment Period or within 5 half-lives of the final dose of the product administered during the previous interventional study, whichever is longer
  4. Having laboratory clinical abnormalities assessed as by the investigator in results of hematology or chemistry assessments performed during Screening
  5. Currently receiving a therapy not permitted during the study
  6. Being pregnant or breastfeeding.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    CSL312

    Ages 2-5 years and 6-11 years will have specific subcutaneous dosing schedules

    Biological: CSL312

Interventions

  • BiologicalCSL312

    Fully human immunoglobulin G subclass 4/lambda recombinant inhibitor monoclonal antibody administered subcutaneously (SC)

    Also known as: Garadacimab

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAE)

    Time frame: Up to Month 12

  2. Percentage of Participants With TEAE

    The percentage of participants was rounded to one place of decimal.

    Time frame: Up to Month 12

  3. Number of TEAE

    Time frame: Up to Month 12

  4. TEAE Rates Per Injection

    The TEAE rate per injection was calculated as the number of TEAE/ number of injections. The number of injections was defined as the total injections a participant received during the Safety Evaluation Period under the dosing regimen to which the TEAE was assigned.

    Time frame: Up to Month 12

  5. TEAE Rates Per Participant-Year

    The TEAE rate per participant year was calculated as number of TEAEs/ participant years. Participant-years of exposure were calculated as the sum of each participant's exposure duration (in years) under the specified dosing regimen or overall. For the time assigned to a dosing regimen, each study day was counted under the corresponding regimen.

    Time frame: Up to Month 12

  6. Maximum Concentration (Cmax) of CSL312 at Steady-state

    Time frame: Up to Month 12

  7. Trough Concentration (Ctrough) of CSL312 at Steady-state

    Time frame: At Months 3, 4, 6, 9, 10, and 12

  8. Time to Maximum Concentration (Tmax) of CSL312 at Steady-State

    Time frame: Up to Month 12

Secondary outcomes

  1. Time-normalized Number of HAE Attacks Per Month

    Time-normalized number of HAE attacks per month during treatment was calculated per participant as: \[Number of HAE attacks / Length of participant treatment in days\] \* 30.4375.

    Time frame: Up to Month 12

  2. Time-normalized Number of HAE Attacks Per Year

    Time-normalized number of HAE attacks per year during treatment was calculated per participant as: \[Number of HAE attacks / Length of participant treatment in days\] \* 365.25.

    Time frame: Up to Month 12

  3. Time-normalized Number of HAE Attacks Treated With On-demand Treatment Per Month

    The time-normalized number of HAE attacks per month treated with on-demand treatment were calculated as follows: \[(Number of HAE attacks treated with on - demand treatment during treatment period)/ Length of participant treatment in days\] ∗ 30.4375.

    Time frame: Up to Month 12

  4. Time-normalized Number of HAE Attacks Treated With On-demand Treatment Per Year

    The time-normalized number of HAE attacks per year treated with on-demand treatment were calculated as follows: \[(Number of HAE attacks treated with on - demand treatment during treatment period)/ Length of participant treatment in days\] ∗ 365.25.

    Time frame: Up to Month 12

  5. Time-normalized Number of Moderate and/or Severe HAE Attacks Per Month

    Time-normalized number of moderate or severe HAE attacks per month during treatment period was calculated per participant as: \[number of moderate or severe HAE attacks / length of participant treatment in days\] \* 30.4375.

    Time frame: Up to Month 12

  6. Time-normalized Number of Moderate and/or Severe HAE Attacks Per Year

    Time-normalized number of moderate or severe HAE attacks per month during treatment period was calculated per participant as: \[number of moderate or severe HAE attacks / length of participant treatment in days\] \* 365.25.

    Time frame: Up to Month 12

  7. Percentage Reduction in the Time-normalized Number of HAE Attacks

    The percentage reduction in the time-normalized number of HAE attacks was calculated within a participant as follows: 100\*\[ 1 - (Time-normalized number of HAE attacks per month during treatment period/Time-normalized number of HAE attacks per month from historical data)\].

    Time frame: Up to Month 12

  8. Number of Participants Experiencing at Least Greater Than or Equal to (>=) 50 Percent (%), >= 70%, >= 90%, or Equal to 100% (Attack-free) Reduction in the Time-normalized Number of HAE Attacks

    A participant was classified as a responder if the percentage reduction in the time-normalized number of HAE attacks under treatment compared to the time-normalized number of HAE attacks documented in the medical records was \>= 50%. Percent Reduction = 100 \* \[1 - (time-normalized number of HAE attacks during corresponding time window / time-normalized number of HAE attacks based on historical data)\]. Here number of participants experiencing at least \>= 50%, \>= 70%, \>= 90%, or equal to 100% (Attack-free) reduction in the time-normalized number of HAE attacks are reported. The number of responders at each reduction category have been reported.

    Time frame: Up to Month 12

  9. Number of Participants Experiencing Serious Adverse Events (SAE), Experiencing Death, Related TEAE, TEAE Leading to Study Discontinuation

    Time frame: Up to Month 12

  10. Percentage of Participants Experiencing SAE, Experiencing Death, Related TEAE, TEAE Leading to Study Discontinuation

    The percentage of participants was rounded to one decimal place.

    Time frame: Up to Month 12

  11. Number of Participants With TEAE by Severity

    Severity of AE was assessed by the investigator and categorized as mild, moderate and severe where: Mild: AE that is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living. Moderate: AE that is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research participant. Severe: AE that interrupts usual activities of daily living, significantly affects clinical status, or may require intensive therapeutic intervention.

    Time frame: Up to Month 12

  12. Percentage of Participants With TEAE by Severity

    Severity of AE was assessed by the investigator and categorized as mild, moderate and severe where: Mild: AE that is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living. Moderate: AE that is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research participant. Severe: AE that interrupts usual activities of daily living, significantly affects clinical status, or may require intensive therapeutic intervention. The percentage of participants was rounded to one place of decimal.

    Time frame: Up to Month 12

  13. Number of Participants With Anti-CSL312 Antibodies

    Time frame: At Day 1, Months 6 and 12

  14. Percentage of Participants With Anti-CSL312 Antibodies

    The percentage of participants was rounded to one place of decimal.

    Time frame: At Day 1, Months 6 and 12

  15. Number of Participants With Adverse Events of Special Interest (AESI)

    AESI included severe hypersensitivity including anaphylaxis. The AESI reported have been identified by investigators and suggestive events were independently identified for further review with a Standardized MedDRA Query (SMQ).

    Time frame: Up to Month 12

  16. Percentage of Participants With AESI

    AESI included severe hypersensitivity including anaphylaxis. The AESI reported have been identified by investigators and suggestive events were independently identified for further review with an SMQ. The percentage of participants was rounded to one place of decimal.

    Time frame: Up to Month 12

  17. FXIIa-mediated Kallikrein Activity

    Time frame: At Months 3, 4, and 12 and pre-dose and post dose at Months 6, 9, and 10

  18. Percent of Baseline FXIIa-mediated Kallikrein Activity

    Percent of Baseline at Visit \[i\] = 100 \* (actual value at Visit \[i\] / Baseline value), where Baseline is defined as the most recent, non-missing value before the first IP administration (including unscheduled visits). Here unit of measure is Percent (%) of FXIIa-mediated Kallikrein Activity.

    Time frame: At Months 3, 4, and 12 and pre-dose and post dose at Months 6, 9, and 10

  19. Number of Participants With Laboratory Findings Reported as AE

    Time frame: Up to Month 12

  20. Percentage of Participants With Laboratory Findings Reported as AE

    The participant data were rounded to one decimal place.

    Time frame: Up to Month 12

07

Results

Posted Jun 2, 2026

Participant flow

This study was conducted at 9 sites in the United States, Australia, Canada, Germany, and Israel.

Participant flow — Overall Study
MilestoneCSL312 (Garadacimab) Q2MCSL312 (Garadacimab) Q1M
Started616
Completed616
Not completed00

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAE)
Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAE)
ParticipantsCSL312 (Garadacimab) Q2MCSL312 (Garadacimab) Q1M
Number of Participants With Treatment Emergent Adverse Events (TEAE)511
PrimaryPercentage of Participants With TEAE

The percentage of participants was rounded to one place of decimal.

Time frame:
Up to Month 12
Reported as:
Number · Percentage of participants
Percentage of Participants With TEAE
Percentage of participantsCSL312 (Garadacimab) Q2MCSL312 (Garadacimab) Q1M
Percentage of Participants With TEAE83.368.8
PrimaryNumber of TEAE
Time frame:
Up to Month 12
Reported as:
Number · Events
Number of TEAE
EventsCSL312 (Garadacimab) Q2MCSL312 (Garadacimab) Q1M
Number of TEAE1451
PrimaryTEAE Rates Per Injection

The TEAE rate per injection was calculated as the number of TEAE/ number of injections. The number of injections was defined as the total injections a participant received during the Safety Evaluation Period under the dosing regimen to which the TEAE was assigned.

Time frame:
Up to Month 12
Reported as:
Number · Number of TEAE per injection
TEAE Rates Per Injection
Number of TEAE per injectionCSL312 (Garadacimab) Q2MCSL312 (Garadacimab) Q1M
TEAE Rates Per Injection0.390.27
PrimaryTEAE Rates Per Participant-Year

The TEAE rate per participant year was calculated as number of TEAEs/ participant years. Participant-years of exposure were calculated as the sum of each participant's exposure duration (in years) under the specified dosing regimen or overall. For the time assigned to a dosing regimen, each study day was counted under the corresponding regimen.

Time frame:
Up to Month 12
Reported as:
Number · Number of TEAE per participant year
TEAE Rates Per Participant-Year
Number of TEAE per participant yearCSL312 (Garadacimab) Q2MCSL312 (Garadacimab) Q1M
TEAE Rates Per Participant-Year2.343.21
PrimaryMaximum Concentration (Cmax) of CSL312 at Steady-state
Time frame:
Up to Month 12
Reported as:
Mean · Nanograms per milliliter (ng/mL)
Maximum Concentration (Cmax) of CSL312 at Steady-state
Nanograms per milliliter (ng/mL)CSL312 (Garadacimab) Q2MCSL312 (Garadacimab) Q1M
Maximum Concentration (Cmax) of CSL312 at Steady-state30374.0 ± 13444.9429100.0 ± 10988.08
PrimaryTrough Concentration (Ctrough) of CSL312 at Steady-state
Time frame:
At Months 3, 4, 6, 9, 10, and 12
Reported as:
Mean · ng/mL
Trough Concentration (Ctrough) of CSL312 at Steady-state
ng/mLCSL312 (Garadacimab) Q2MCSL312 (Garadacimab) Q1M
Month 3—10494.7 ± 9956.38
Month 43147.3 ± 2483.85—
Month 63478.0 ± 1897.329645.0 ± 4888.47
Month 9—10003.3 ± 5232.68
Month 104907.5 ± 2429.46—
Month 124211.0 ± 2597.938535.6 ± 5135.63
PrimaryTime to Maximum Concentration (Tmax) of CSL312 at Steady-State
Time frame:
Up to Month 12
Reported as:
Median · Days
Time to Maximum Concentration (Tmax) of CSL312 at Steady-State
DaysCSL312 (Garadacimab) Q2MCSL312 (Garadacimab) Q1M
Time to Maximum Concentration (Tmax) of CSL312 at Steady-State6.939 (5.95 to 7.96)6.985 (6.00 to 8.70)
SecondaryTime-normalized Number of HAE Attacks Per Month

Time-normalized number of HAE attacks per month during treatment was calculated per participant as: \[Number of HAE attacks / Length of participant treatment in days\] \* 30.4375.

Time frame:
Up to Month 12
Reported as:
Median · Number of HAE attacks per month
Time-normalized Number of HAE Attacks Per Month
Number of HAE attacks per monthCSL312 (Garadacimab) Q2MCSL312 (Garadacimab) Q1M
Time-normalized Number of HAE Attacks Per Month0.000 (0.0000 to 0.0843)0.000 (0.000 to 0.1682)
SecondaryTime-normalized Number of HAE Attacks Per Year

Time-normalized number of HAE attacks per year during treatment was calculated per participant as: \[Number of HAE attacks / Length of participant treatment in days\] \* 365.25.

Time frame:
Up to Month 12
Reported as:
Median · Number of HAE attacks per year
Time-normalized Number of HAE Attacks Per Year
Number of HAE attacks per yearCSL312 (Garadacimab) Q2MCSL312 (Garadacimab) Q1M
Time-normalized Number of HAE Attacks Per Year0.000 (0.000 to 1.0118)0.000 (0.000 to 2.0180)
SecondaryTime-normalized Number of HAE Attacks Treated With On-demand Treatment Per Month

The time-normalized number of HAE attacks per month treated with on-demand treatment were calculated as follows: \[(Number of HAE attacks treated with on - demand treatment during treatment period)/ Length of participant treatment in days\] ∗ 30.4375.

Time frame:
Up to Month 12
Reported as:
Median · Number of HAE attacks per month
Time-normalized Number of HAE Attacks Treated With On-demand Treatment Per Month
Number of HAE attacks per monthCSL312 (Garadacimab) Q2MCSL312 (Garadacimab) Q1M
Time-normalized Number of HAE Attacks Treated With On-demand Treatment Per Month0.000 (0.000 to 0.0843)0.000 (0.000 to 0.0850)
SecondaryTime-normalized Number of HAE Attacks Treated With On-demand Treatment Per Year

The time-normalized number of HAE attacks per year treated with on-demand treatment were calculated as follows: \[(Number of HAE attacks treated with on - demand treatment during treatment period)/ Length of participant treatment in days\] ∗ 365.25.

Time frame:
Up to Month 12
Reported as:
Median · Number of HAE attacks per year
Time-normalized Number of HAE Attacks Treated With On-demand Treatment Per Year
Number of HAE attacks per yearCSL312 (Garadacimab) Q2MCSL312 (Garadacimab) Q1M
Time-normalized Number of HAE Attacks Treated With On-demand Treatment Per Year0.000 (0.000 to 1.0118)0.000 (0.000 to 1.0203)
SecondaryTime-normalized Number of Moderate and/or Severe HAE Attacks Per Month

Time-normalized number of moderate or severe HAE attacks per month during treatment period was calculated per participant as: \[number of moderate or severe HAE attacks / length of participant treatment in days\] \* 30.4375.

Time frame:
Up to Month 12
Reported as:
Median · Number of HAE attacks per month
Time-normalized Number of Moderate and/or Severe HAE Attacks Per Month
Number of HAE attacks per monthCSL312 (Garadacimab) Q2MCSL312 (Garadacimab) Q1M
Time-normalized Number of Moderate and/or Severe HAE Attacks Per Month0.000 (0.000 to 0.0843)0.000 (0.000 to 0.0843)
SecondaryTime-normalized Number of Moderate and/or Severe HAE Attacks Per Year

Time-normalized number of moderate or severe HAE attacks per month during treatment period was calculated per participant as: \[number of moderate or severe HAE attacks / length of participant treatment in days\] \* 365.25.

Time frame:
Up to Month 12
Reported as:
Median · Number of HAE attacks per year
Time-normalized Number of Moderate and/or Severe HAE Attacks Per Year
Number of HAE attacks per yearCSL312 (Garadacimab) Q2MCSL312 (Garadacimab) Q1M
Time-normalized Number of Moderate and/or Severe HAE Attacks Per Year0.000 (0.000 to 1.0118)0.000 (0.000 to 1.0118)
SecondaryPercentage Reduction in the Time-normalized Number of HAE Attacks

The percentage reduction in the time-normalized number of HAE attacks was calculated within a participant as follows: 100\*\[ 1 - (Time-normalized number of HAE attacks per month during treatment period/Time-normalized number of HAE attacks per month from historical data)\].

Time frame:
Up to Month 12
Reported as:
Mean · Percentage reduction in HAE attacks
Percentage Reduction in the Time-normalized Number of HAE Attacks
Percentage reduction in HAE attacksCSL312 (Garadacimab) Q2MCSL312 (Garadacimab) Q1M
Percentage Reduction in the Time-normalized Number of HAE Attacks99.297 ± 1.721193.535 ± 12.9513
SecondaryNumber of Participants Experiencing at Least Greater Than or Equal to (>=) 50 Percent (%), >= 70%, >= 90%, or Equal to 100% (Attack-free) Reduction in the Time-normalized Number of HAE Attacks

A participant was classified as a responder if the percentage reduction in the time-normalized number of HAE attacks under treatment compared to the time-normalized number of HAE attacks documented in the medical records was \>= 50%. Percent Reduction = 100 \* \[1 - (time-normalized number of HAE attacks during corresponding time window / time-normalized number of HAE attacks based on historical data)\]. Here number of participants experiencing at least \>= 50%, \>= 70%, \>= 90%, or equal to 100% (Attack-free) reduction in the time-normalized number of HAE attacks are reported. The number of responders at each reduction category have been reported.

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of Participants Experiencing at Least Greater Than or Equal to (>=) 50 Percent (%), >= 70%, >= 90%, or Equal to 100% (Attack-free) Reduction in the Time-normalized Number of HAE Attacks
ParticipantsCSL312 (Garadacimab) Q2MCSL312 (Garadacimab) Q1M
>= 50%615
>= 70%615
>= 90%611
Attack free (Reduction of 100%)510
SecondaryNumber of Participants Experiencing Serious Adverse Events (SAE), Experiencing Death, Related TEAE, TEAE Leading to Study Discontinuation
Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of Participants Experiencing Serious Adverse Events (SAE), Experiencing Death, Related TEAE, TEAE Leading to Study Discontinuation
ParticipantsCSL312 (Garadacimab) Q2MCSL312 (Garadacimab) Q1M
SAE01
Experiencing Death00
Related TEAE13
TEAE leading to study discontinuation00
SecondaryPercentage of Participants Experiencing SAE, Experiencing Death, Related TEAE, TEAE Leading to Study Discontinuation

The percentage of participants was rounded to one decimal place.

Time frame:
Up to Month 12
Reported as:
Number · Percentage of participants
Percentage of Participants Experiencing SAE, Experiencing Death, Related TEAE, TEAE Leading to Study Discontinuation
Percentage of participantsCSL312 (Garadacimab) Q2MCSL312 (Garadacimab) Q1M
SAE06.3
Experiencing Death00
Related TEAE16.718.8
TEAE leading to study discontinuation00
SecondaryNumber of Participants With TEAE by Severity

Severity of AE was assessed by the investigator and categorized as mild, moderate and severe where: Mild: AE that is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living. Moderate: AE that is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research participant. Severe: AE that interrupts usual activities of daily living, significantly affects clinical status, or may require intensive therapeutic intervention.

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of Participants With TEAE by Severity
ParticipantsCSL312 (Garadacimab) Q2MCSL312 (Garadacimab) Q1M
Mild49
Moderate35
Severe02
SecondaryPercentage of Participants With TEAE by Severity

Severity of AE was assessed by the investigator and categorized as mild, moderate and severe where: Mild: AE that is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living. Moderate: AE that is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research participant. Severe: AE that interrupts usual activities of daily living, significantly affects clinical status, or may require intensive therapeutic intervention. The percentage of participants was rounded to one place of decimal.

Time frame:
Up to Month 12
Reported as:
Number · Percentage of participants
Percentage of Participants With TEAE by Severity
Percentage of participantsCSL312 (Garadacimab) Q2MCSL312 (Garadacimab) Q1M
Mild66.756.3
Moderate50.031.3
Severe012.5
SecondaryNumber of Participants With Anti-CSL312 Antibodies
Time frame:
At Day 1, Months 6 and 12
Reported as:
Count of participants · Participants
Number of Participants With Anti-CSL312 Antibodies
ParticipantsCSL312 (Garadacimab) Q2MCSL312 (Garadacimab) Q1M
Day 1: Positive00
Month 6: Positive02
Month 12: Positive02
SecondaryPercentage of Participants With Anti-CSL312 Antibodies

The percentage of participants was rounded to one place of decimal.

Time frame:
At Day 1, Months 6 and 12
Reported as:
Number · Percentage of participants
Percentage of Participants With Anti-CSL312 Antibodies
Percentage of participantsCSL312 (Garadacimab) Q2MCSL312 (Garadacimab) Q1M
Day 1: Positive00
Month 6: Positive013.3
Month 12: Positive012.5
SecondaryNumber of Participants With Adverse Events of Special Interest (AESI)

AESI included severe hypersensitivity including anaphylaxis. The AESI reported have been identified by investigators and suggestive events were independently identified for further review with a Standardized MedDRA Query (SMQ).

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events of Special Interest (AESI)
ParticipantsCSL312 (Garadacimab) Q2MCSL312 (Garadacimab) Q1M
Investigator00
SMQ13
SecondaryPercentage of Participants With AESI

AESI included severe hypersensitivity including anaphylaxis. The AESI reported have been identified by investigators and suggestive events were independently identified for further review with an SMQ. The percentage of participants was rounded to one place of decimal.

Time frame:
Up to Month 12
Reported as:
Number · Percentage of participants
Percentage of Participants With AESI
Percentage of participantsCSL312 (Garadacimab) Q2MCSL312 (Garadacimab) Q1M
Investigator00
SMQ16.718.8
SecondaryFXIIa-mediated Kallikrein Activity
Time frame:
At Months 3, 4, and 12 and pre-dose and post dose at Months 6, 9, and 10
Reported as:
Mean · DeltaA405 nanometer per minute
FXIIa-mediated Kallikrein Activity
DeltaA405 nanometer per minuteCSL312 (Garadacimab) Q2MCSL312 (Garadacimab) Q1M
Month 3—0.2039 ± 0.0927
Month 40.2632 ± 0.0904—
Month 6: Pre-dose0.2932 ± 0.06790.1863 ± 0.0979
Month 6: Post-dose—0.1162 ± 0.0811
Month 9: Pre-dose—0.1910 ± 0.0889
Month 9: Post-dose—0.1145 ± 0.1606
Month 10: Pre-dose0.2703 ± 0.0400—
Month 10: Post-dose0.1002 ± 0.1190—
Month 120.2368 ± 0.09380.2049 ± 0.0870
SecondaryPercent of Baseline FXIIa-mediated Kallikrein Activity

Percent of Baseline at Visit \[i\] = 100 \* (actual value at Visit \[i\] / Baseline value), where Baseline is defined as the most recent, non-missing value before the first IP administration (including unscheduled visits). Here unit of measure is Percent (%) of FXIIa-mediated Kallikrein Activity.

Time frame:
At Months 3, 4, and 12 and pre-dose and post dose at Months 6, 9, and 10
Reported as:
Mean · % FXIIa-mediated Kallikrein Activity
Percent of Baseline FXIIa-mediated Kallikrein Activity
% FXIIa-mediated Kallikrein ActivityCSL312 (Garadacimab) Q2MCSL312 (Garadacimab) Q1M
Month 3—122.45 ± 84.860
Month 4166.43 ± 149.522—
Month 6: Pre-dose168.12 ± 117.752128.12 ± 134.291
Month 6: Post-dose—62.54 ± 38.197
Month 9: Pre-dose—114.56 ± 88.924
Month 9: Post-dose—70.07 ± 54.403
Month 10: Pre-dose179.26 ± 149.818—
Month 10: Post-dose98.41 ± 151.830—
Month 12180.09 ± 165.106130.44 ± 105.945
SecondaryNumber of Participants With Laboratory Findings Reported as AE
Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Findings Reported as AE
ParticipantsCSL312 (Garadacimab) Q2MCSL312 (Garadacimab) Q1M
Number of Participants With Laboratory Findings Reported as AE01
SecondaryPercentage of Participants With Laboratory Findings Reported as AE

The participant data were rounded to one decimal place.

Time frame:
Up to Month 12
Reported as:
Number · Percentage of participants
Percentage of Participants With Laboratory Findings Reported as AE
Percentage of participantsCSL312 (Garadacimab) Q2MCSL312 (Garadacimab) Q1M
Percentage of Participants With Laboratory Findings Reported as AE06.3

Adverse events

Collected over Up to Month 15. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CSL312 (Garadacimab) Q2M0/6 (0%)0/6 (0%)5/6 (83.3%)
CSL312 (Garadacimab) Q1M0/16 (0%)1/16 (6.3%)11/16 (68.8%)
Most frequent serious events
Most frequent serious events
EventCSL312 (Garadacimab) Q2MCSL312 (Garadacimab) Q1M
Skull fractureInjury, poisoning and procedural complications0/61/16
Most frequent other events
Showing 10 of 36
Most frequent other events
EventCSL312 (Garadacimab) Q2MCSL312 (Garadacimab) Q1M
Upper respiratory tract infectionInfections and infestations2/66/16
Ear infectionInfections and infestations1/61/16
COVID-19Infections and infestations1/60/16
Gastroenteritis norovirusInfections and infestations1/60/16
Gastroenteritis viralInfections and infestations1/60/16
Otitis mediaInfections and infestations1/60/16
Periorbital cellulitisInfections and infestations1/60/16
Viral infectionInfections and infestations1/60/16
Viral upper respiratory tract infectionInfections and infestations1/60/16
Injection site painGeneral disorders1/60/16

Baseline characteristics

Analysis was performed on safety analysis set (SAS). The SAS comprised all participants enrolled in the study who received at least 1 dose of the investigational product (IP).

Age, Categorical
Age, Categorical(Participants)CSL312 (Garadacimab) Q2MCSL312 (Garadacimab) Q1MTotal
<=18 years61622
Between 18 and 65 years000
>=65 years000
Age, Continuous
Age, Continuous(Years)CSL312 (Garadacimab) Q2MCSL312 (Garadacimab) Q1MTotal
Mean3.7 ± 1.519.3 ± 1.347.7 ± 2.88
Sex: Female, Male
Sex: Female, Male(Participants)CSL312 (Garadacimab) Q2MCSL312 (Garadacimab) Q1MTotal
Female145
Male51217
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)CSL312 (Garadacimab) Q2MCSL312 (Garadacimab) Q1MTotal
Hispanic or Latino022
Not Hispanic or Latino61420
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)CSL312 (Garadacimab) Q2MCSL312 (Garadacimab) Q1MTotal
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American000
White61521
More than one race000
Unknown or Not Reported000
08

Study locations

13 sites
  • Research Solutions of Arizona
    Litchfield Park, Arizona 85340, United States
  • Medical Research of Arizona
    Scottsdale, Arizona 85251, United States
  • Donald S. Levy M.D.
    Orange, California 92868, United States
  • Raffi Tachdjian MD, Inc.
    Santa Monica, California 90404, United States
  • Bernstein Clinical Research
    Cincinnati, Ohio 45236, United States
  • PennState Health Milton S. Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • AARA Research Center
    Dallas, Texas 75231, United States
  • Campbelltown Hospital, Western Sydney University
    Campbelltown, NSW 2560, Australia
  • Ottawa Allergy Research Corp
    Ottawa, K1H1E4, Canada
  • HZRM Hämophilie Zentrum Rhein Main GmbH
    Frankfurt am Main, Hesse 60596, Germany
  • Charité - Universitätsmedizin Berlin
    Berlin, 12203, Germany
  • Universitätsklinikum Frankfurt
    Frankfurt am Main, 60590, Germany
  • Barzilai University Medical Center
    Ashkelon, 7830604, Israel
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — CSL will consider on a case-by-case basis requests to share Individual Patient Data (IPD) with external bona-fide, qualified scientific and medical researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Requests for IPD will generally be considered once review by major regulatory authorities (ie FDA, EMA) is complete and the primary publication is available.

Access criteria: Proposed research should seek to answer a previously unanswered important medical or scientific question. Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD. If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in Nov 2025, 29 months.

Results were first posted in Jun 2026, 6 months after primary completion.

Of 46 industry-sponsored phase 3 interventional studies under Angioedemas, Hereditary, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 33. This study's 29 months is above that.

Counting every sponsor, half of 46 studies reached it within 22 months; a quarter within 16 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2023
First posted
Apr 19, 2023
StartActual
May 30, 2023
Primary completionActual
Nov 19, 2025
CompletionActual
Nov 19, 2025
Results first posted
Jun 2, 2026
Last update
Jun 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05819775
Lead sponsor
CSL Behring
Responsible party
Sponsor
First posted
Apr 19, 2023
Start date
May 30, 2023
Primary completion
Nov 19, 2025
Completion
Nov 19, 2025
Results posted
Jun 2, 2026
Last update
Jun 2, 2026

Study contacts

Study Director
study director · CSL Behring

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Garadacimab

Start the discussion